Cell-Based Therapy of Cardiovascular Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Cardiovascular System".

Deadline for manuscript submissions: closed (1 December 2022) | Viewed by 10486

Special Issue Editors

National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, 169609, Singapore
Interests: heart disease; cardiovascular; diabetes; molecular and cellular therapeutics; stem cells
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
National Clinical Research Center for Geriatric Diseases in China, Chinese PLA General Hospital, Beijing 100853, China
Interests: heart disease; cardiovascular; molecular imaging; cellular therapeutics; stem cells

Special Issue Information

Dear Colleagues,

Despite advances in medicine, cardiovascular diseases (CVDs) are still the leading cause of death worldwide. According to WHO key facts, about 17.9 million people died from CVDs in 2019, representing 32% of all global deaths (https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)#:~:text=Key%20facts,to%20heart%20attack%20and%20stroke). The development of stem cell biology has enabled cell-based therapy as a promising approach to promote the repair of injured tissue and replenish new and functional cells.

In this Special Issue, we invite cardiologists and cell and developmental biologists to submit research on the strategies to boost and improve our understanding of the mechanism of cell-based therapy for the treatment of cardiovascular diseases. Topics include but are not limited to pluripotent stem cells, multipotent stem cells, and progenitor cells and their derivatives, including nanovesicles and exosomes, novel cellular delivery approaches and monitoring modality, preclinical studies, etc. We hope this Special Issue will provide new insights into understanding the key factors promoting cell-based therapy efficacy, attesting new cellular or molecular interventions, and promoting novel cellular therapeutic strategies for the treatment of cardiovascular diseases.

Dr. Lei Ye
Prof. Dr. Feng Cao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart diseases
  • stem cell biology
  • cell transfer therapy
  • tissue engineering
  • nanomedicine
  • cell derivatives

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

17 pages, 2814 KiB  
Article
Optogenetic Control of Engrafted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Live Mice: A Proof-of-Concept Study
by Jyotsna Joshi, Bing Xu, Michael Rubart, Yun Chang, Xiaoping Bao, Hari P. Chaliki, Luis R. Scott and Wuqiang Zhu
Cells 2022, 11(6), 951; https://doi.org/10.3390/cells11060951 - 10 Mar 2022
Cited by 2 | Viewed by 3811
Abstract
Background: Cellular transplantation has emerged as promising approach for treating cardiac diseases. However, a poor engraftment rate limits our understanding on how transplanted cardiomyocytes contribute to cardiac function in the recipient’s heart. Methods: The CRISPR/Cas9 technique was employed for stable and constitutive gene [...] Read more.
Background: Cellular transplantation has emerged as promising approach for treating cardiac diseases. However, a poor engraftment rate limits our understanding on how transplanted cardiomyocytes contribute to cardiac function in the recipient’s heart. Methods: The CRISPR/Cas9 technique was employed for stable and constitutive gene expression in human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs). Myocardial infarction was induced in adult immunodeficient mice, followed by intramyocardial injection of hiPSC-CMs expressing either CCND2/channelrhodopsin 2 (hiPSC-CCND2OE/ChR2OECMs) or CCND2/luciferase (hiPSC-CCND2OE/LuciOECMs). Six months later, hemodynamics and intramural electrocardiogram were recorded upon blue light illuminations in anesthetized, open-chest mice. Results: Blue light resets automaticity of spontaneously beating hiPSC-CCND2OE/ChR2OECMs in culture, but not that of hiPSC-CCND2OE/LuciOECMs. Response to blue light was also observed in mice carrying large (>106 cells) intracardiac grafts of hiPSC-CCND2OE/ChR2OECM but not in mice carrying hiPSC-CCND2OE/LuciOECMs. The former exhibited single premature ventricular contractions upon light illumination or ventricular quadrigeminy upon second-long illuminations. At the onset of premature ventricular contractions, maximal systolic ventricular pressure decreased while ventricular volume rose concomitantly. Light-induced changes reversed upon resumption of sinus rhythm. Conclusions: We established an in vivo model for optogenetic-based modulation of the excitability of donor cardiomyocytes in a functional, reversible, and localized manner. This approach holds unique value for studying electromechanical coupling and molecular interactions between donor cardiomyocytes and recipient hearts in live animals. Full article
(This article belongs to the Special Issue Cell-Based Therapy of Cardiovascular Diseases)
Show Figures

Graphical abstract

Review

Jump to: Research, Other

27 pages, 886 KiB  
Review
The Role of Amino Acids in Endothelial Biology and Function
by Meng Li, Yanqing Wu and Lei Ye
Cells 2022, 11(8), 1372; https://doi.org/10.3390/cells11081372 - 18 Apr 2022
Cited by 16 | Viewed by 4116
Abstract
The vascular endothelium acts as an important component of the vascular system. It is a barrier between the blood and vessel wall. It plays an important role in regulating blood vessel tone, permeability, angiogenesis, and platelet functions. Several studies have shown that amino [...] Read more.
The vascular endothelium acts as an important component of the vascular system. It is a barrier between the blood and vessel wall. It plays an important role in regulating blood vessel tone, permeability, angiogenesis, and platelet functions. Several studies have shown that amino acids (AA) are key regulators in maintaining vascular homeostasis by modulating endothelial cell (EC) proliferation, migration, survival, and function. This review summarizes the metabolic and signaling pathways of AAs in ECs and discusses the importance of AA homeostasis in the functioning of ECs and vascular homeostasis. It also discusses the challenges in understanding the role of AA in the development of cardiovascular pathophysiology and possible directions for future research. Full article
(This article belongs to the Special Issue Cell-Based Therapy of Cardiovascular Diseases)
Show Figures

Figure 1

Other

Jump to: Research, Review

7 pages, 1810 KiB  
Opinion
Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
by Jacquelynn Morrissey, Fernanda C. P. Mesquita, Lourdes Chacon-Alberty and Camila Hochman-Mendez
Cells 2022, 11(13), 2092; https://doi.org/10.3390/cells11132092 - 30 Jun 2022
Cited by 2 | Viewed by 1838
Abstract
Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone [...] Read more.
Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) to mesenchymal stromal cells (MSCs), which are believed to elicit benefits through paracrine activity. Here, we examined MSCs from the BMMNCs of heart failure patients enrolled in the FOCUS-CCTRN trial. We sought to identify differences in MSCs between patients who improved and those who declined in heart function, regardless of treatment received. Although we did not observe differences in the cell profile of MSCs between groups, we did find significant differences in the MSC secretome profile between patients who improved or declined. We conclude that “mining” the MSC secretome may provide clues to better understand the impact of patient characteristics on outcomes after cell therapy and this knowledge can inform future cell therapy trials. Full article
(This article belongs to the Special Issue Cell-Based Therapy of Cardiovascular Diseases)
Show Figures

Figure 1

Back to TopTop